StockData
Palvella Therapeutics, Inc. logo

Palvella Therapeutics, Inc. (PVLA) shareholders

PVLANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$144.35−0.25 (-0.17%)

Close on Nov 17, 2026Market cap $2.08BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
97.8%
14M of 14M shares
Institutional holders
197
38 new, 19 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
3 buys · 76 sales
Net sold $15.07M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Kaupinen Wes
Joint filing with Christine L. Kaupinen (13.90%), Wesley H. Kaupinen 2019 Irrevocable Trust dated February 28, 2019 (6.90%) and 2 more
1,644,86914.60%13D (active)Dec 13, 2024
Jennison Associates LLC1,101,6527.70%13G (passive) amendmentSep 30, 2026
Prudential Financial Inc962,3746.70%13G (passive)Jun 30, 2026
Bvf Partners L P/Il
Joint filing with Bvf Inc/Il (7.10%), Lampert Mark N (7.10%) and 1 more
879,0097.10%13G (passive) amendmentDec 31, 2025
Aaron Cowen
Joint filing with Suvretta Capital Management, LLC (7.40%), Averill Master Fund, Ltd. (6.50%)
822,4007.40%13G (passive) amendmentSep 30, 2025
BlackRock, Inc.812,9535.70%13G (passive)Jun 30, 2026
Mathew P. Arens
Joint filing with First Light Asset Management, LLC (5.34%)
769,1175.34%13G (passive) amendmentJun 30, 2026
Frazier Life Sciences Public Fund, L.P.
Joint filing with Fhmlsp, L.P. (6.00%), Fhmlsp, L.L.C. (6.00%)
706,3606.00%13G (passive) amendmentDec 31, 2025
James N. Topper
Joint filing with Patrick J. Heron (6.30%), Albert Cha (6.20%) and 1 more
690,0126.30%13G (passive) amendmentMar 31, 2025
Samsara BioCapital GP, LLC
Joint filing with Samsara BioCapital, L.P. (6.10%), Srinivas Akkaraju (6.10%)
679,4866.10%13G (passive)Dec 13, 2024
ADAR1 Capital Management, LLC
Joint filing with ADAR1 Capital Management GP, LLC (10.50%), Daniel Schneeberger (10.50%)
138,64110.50%13G (passive)Jul 24, 2024

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of PVLAValueChange% of portfolio
Suvretta Capital Management, LLC1,135,4067.88%$173.51M−18,0903.17%
Jennison Associates LLC960,6196.67%$146.80M+320,0080.09%
BlackRock, Inc.918,3576.37%$140.34M+231,5040.00%
Frazier Life Sciences Management, L.P.882,4006.12%$134.85M–2.94%
First Light Asset Management, LLC771,9015.36%$117.96M−208,8577.17%
Bvf Inc/Il672,7894.67%$102.82M−288,2002.63%
State Street Corp653,1724.53%$99.82M+194,1730.00%
Price T Rowe Associates Inc /Md/638,8684.43%$97.63M+236,3040.01%
Vanguard Capital Management LLC513,7943.57%$78.52M+36,5000.00%
Frontier Capital Management Co LLC478,8333.32%$73.18M+104,7980.68%
Federated Hermes, Inc.433,0153.01%$66.17M–0.10%
Woodline Partners LP317,5172.20%$48.52M–0.15%
Orbimed Advisors LLC292,3602.03%$44.68M+157,7600.83%
Geode Capital Management, LLC276,1641.92%$42.21M+70,5550.00%
Siren, L.L.C.257,4851.79%$39.35M–0.80%
Primecap Management Co/Ca/256,1821.78%$39.15M+61,1520.02%
Alliancebernstein L.P.253,1681.76%$31.56M−9,6670.01%
Eventide Asset Management, LLC231,4841.61%$35.38M−1,7640.47%
Emerald Advisers, LLC229,4861.59%$35.07M+67,9860.83%
FMR LLC214,8411.49%$32.83M−9670.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202619714M97.8%38 / 8943 / 192M2M
Q1 202618013M92.0%65 / 6530 / 225M1M
Q4 202514010M67.7%53 / 4130 / 123M2M
Q3 20251009M59.2%43 / 2320 / 84M1M
Q2 2025656M41.0%26 / 199 / 22M1M
Q1 2025415M35.6%15 / 94 / 71M0M
Q4 2024334M28.0%33 / 00 / 04M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

179 funds held PVLA in Q2 2026, 34% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of PVLAValue% of fundAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF408,6782.84%$62.45M0.58%Jun 30, 2026
Vanguard Total Stock Market Index Fund388,3902.70%$59.35M0.00%Jun 30, 2026
iShares Russell 2000 ETF281,5861.95%$43.03M0.05%Jun 30, 2026
Federated Hermes Kaufmann Fund276,5561.92%$38.45M0.78%Jul 31, 2026
Eventide Healthcare & Life Sciences Fund231,4841.61%$35.38M1.98%Jun 30, 2026
PRIMECAP Odyssey Aggressive Growth Fund209,8251.46%$29.17M0.39%Jul 31, 2026
PGIM Jennison Small Company Fund202,9001.41%$31.01M0.89%Jun 30, 2026
PGIM Jennison Health Sciences Fund183,0371.27%$21.68M1.56%May 29, 2026
T. Rowe Price New Horizons Fund, Inc.164,1441.14%$25.08M0.17%Jun 30, 2026
Federated Hermes Kaufmann Small Cap Fund150,5001.04%$20.93M0.73%Jul 31, 2026
T. Rowe Price Health Sciences Fund, Inc.144,2201.00%$22.04M0.18%Jun 30, 2026
Fidelity Small Cap Growth Fund143,7401.00%$19.99M0.23%Jul 31, 2026
Fidelity Small Cap Index Fund120,0680.83%$16.69M0.05%Jul 31, 2026
Vanguard Extended Market Index Fund113,5860.79%$17.36M0.02%Jun 30, 2026
AB Small Cap Growth Portfolio109,4980.76%$16.73M0.53%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Wes KaupinenPresident and CEO, Director, 10% owner1,607,22811.15%Feb 9, 2026
Jeffrey S. MartiniChief Scientific Officer0–Nov 12, 2026
Kathleen GoinChief Operating Officer0–Oct 23, 2026
Matthew E. KorenbergCFO, Treasurer1,0000.01%Jun 16, 2026
Ashley Hartmann KlineChief Commercial Officer––Feb 9, 2026
Palvella Therapeutics, Inc.CFO and Treasurer––Feb 7, 2025
George M. JenkinsDirector146,1321.01%Oct 14, 2026
Christopher P. KiritsyDirector2500.00%Sep 4, 2026
Matthew PaulsDirector––Jul 1, 2026
John DouxDirector––Jun 12, 2026
Tadd S. WesselDirector––Jun 12, 2026
Elaine J. HeronDirector53,6910.37%Jun 12, 2026
Todd C. DavisDirector112,5470.78%Jun 12, 2026
James A. GeraghtyDirector0–Dec 12, 2024
Value Fund L. P. Biotechnology–772,3245.36%Dec 17, 2024
Ii Gp Llc Bvf–––Dec 17, 2024
Partners L. P/Il Bvf–––Dec 17, 2024
Mark N. Lampert–425,3462.95%Dec 17, 2024
Value Trading Fund OS LP Biotechnology–––Dec 17, 2024
Partners OS Ltd. BVF–2,233,07415.50%Dec 17, 2024
Value Fund Ii Lp Biotechnology–––Dec 17, 2024
I. Gp Llc Bvf–282,2231.96%Dec 17, 2024
Inc/Il Bvf–2,408,20716.71%Dec 17, 2024
Gp Holdings Llc Bvf–8,581,17159.56%Dec 17, 2024
Investments LP Dellora–141,0790.98%Dec 16, 2024

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Jeffrey S. Martini
Chief Scientific Officer
Nov 11, 2026Sale(10b5-1 plan)−200$169.78$33.96K0
Jeffrey S. Martini
Chief Scientific Officer
Nov 11, 2026Sale(10b5-1 plan)−600$168.73$101.24K200
Jeffrey S. Martini
Chief Scientific Officer
Nov 11, 2026Sale(10b5-1 plan)−1,200$167.75$201.30K800
Jeffrey S. Martini
Chief Scientific Officer
Nov 11, 2026Sale(10b5-1 plan)−1,133$166.76$188.94K2,000
Jeffrey S. Martini
Chief Scientific Officer
Nov 11, 2026Sale(10b5-1 plan)−1,467$165.78$243.20K3,133
Jeffrey S. Martini
Chief Scientific Officer
Nov 11, 2026Sale(10b5-1 plan)−1,650$164.14$270.83K4,600
Jeffrey S. Martini
Chief Scientific Officer
Nov 11, 2026Option exercise+6,250$9.79$61.19K6,250
Jeffrey S. Martini
Chief Scientific Officer
Nov 10, 2026Sale(10b5-1 plan)−800$172.12$137.70K0
Jeffrey S. Martini
Chief Scientific Officer
Nov 10, 2026Sale(10b5-1 plan)−550$169.03$92.96K800
Jeffrey S. Martini
Chief Scientific Officer
Nov 10, 2026Sale(10b5-1 plan)−200$167.81$33.56K1,350
Jeffrey S. Martini
Chief Scientific Officer
Nov 10, 2026Sale(10b5-1 plan)−1,500$166.91$250.37K1,550
Jeffrey S. Martini
Chief Scientific Officer
Nov 10, 2026Sale(10b5-1 plan)−1,651$165.85$273.81K3,050
Jeffrey S. Martini
Chief Scientific Officer
Nov 10, 2026Sale(10b5-1 plan)−1,449$164.85$238.87K4,701
Jeffrey S. Martini
Chief Scientific Officer
Nov 10, 2026Sale(10b5-1 plan)−100$163.34$16.33K6,150
Jeffrey S. Martini
Chief Scientific Officer
Nov 10, 2026Option exercise+1,984$9.79$19.42K6,250
Jeffrey S. Martini
Chief Scientific Officer
Nov 10, 2026Option exercise+4,266$7.53$32.12K4,266
Kathleen Goin
Chief Operating Officer
Oct 21, 2026Sale(10b5-1 plan)−607$126.19$76.60K0
Kathleen Goin
Chief Operating Officer
Oct 21, 2026Sale(10b5-1 plan)−1,663$125.16$208.15K607
Kathleen Goin
Chief Operating Officer
Oct 21, 2026Sale(10b5-1 plan)−2,043$123.62$252.56K2,270
Kathleen Goin
Chief Operating Officer
Oct 21, 2026Option exercise+2,148$9.08$19.50K4,313
Kathleen Goin
Chief Operating Officer
Oct 21, 2026Option exercise+2,165$7.14$15.46K2,165
George M. Jenkins
Director
Oct 14, 2026Sale(10b5-1 plan)−505$126.55$63.91K132,616
George M. Jenkins
Director
Oct 14, 2026Sale(10b5-1 plan)−597$125.33$74.82K133,121
George M. Jenkins
Director
Oct 14, 2026Sale(10b5-1 plan)−920$124.37$114.42K133,718
George M. Jenkins
Director
Oct 14, 2026Sale(10b5-1 plan)−2,604$123.29$321.05K134,638
George M. Jenkins
Director
Oct 14, 2026Sale(10b5-1 plan)−2,072$122.62$254.06K137,242
George M. Jenkins
Director
Oct 14, 2026Sale(10b5-1 plan)−476$121.14$57.66K139,314
George M. Jenkins
Director
Oct 13, 2026Sale(10b5-1 plan)−922$133.72$123.29K139,790
George M. Jenkins
Director
Oct 13, 2026Sale(10b5-1 plan)−579$132.40$76.66K140,712
George M. Jenkins
Director
Oct 13, 2026Sale(10b5-1 plan)−1,035$131.49$136.09K141,291
George M. Jenkins
Director
Oct 13, 2026Sale(10b5-1 plan)−990$130.48$129.18K142,326
George M. Jenkins
Director
Oct 13, 2026Sale(10b5-1 plan)−1,644$129.23$212.45K143,316
George M. Jenkins
Director
Oct 13, 2026Sale(10b5-1 plan)−2,004$128.52$257.56K144,960
George M. Jenkins
Director
Oct 12, 2026Sale(10b5-1 plan)−817$136.44$111.48K146,964
George M. Jenkins
Director
Oct 12, 2026Sale(10b5-1 plan)−1,447$135.50$196.06K147,781
George M. Jenkins
Director
Oct 12, 2026Sale(10b5-1 plan)−3,335$134.21$447.59K149,228
George M. Jenkins
Director
Oct 12, 2026Sale(10b5-1 plan)−2,458$133.25$327.52K152,563
George M. Jenkins
Director
Oct 12, 2026Sale(10b5-1 plan)−5,095$132.62$675.68K155,021
Kathleen Goin
Chief Operating Officer
Sep 16, 2026Option exercise+2,148$9.08$19.50K4,302
Kathleen Goin
Chief Operating Officer
Sep 16, 2026Option exercise+2,154$7.14$15.38K2,154
Kathleen Goin
Chief Operating Officer
Sep 16, 2026Sale(10b5-1 plan)−1,659$151.16$250.77K2,643
Kathleen Goin
Chief Operating Officer
Sep 16, 2026Sale(10b5-1 plan)−989$152.36$150.68K1,654
Kathleen Goin
Chief Operating Officer
Sep 16, 2026Sale(10b5-1 plan)−1,654$153.24$253.46K0
George M. Jenkins
Director
Sep 15, 2026Sale(10b5-1 plan)−263$150.40$39.56K160,676
George M. Jenkins
Director
Sep 15, 2026Sale(10b5-1 plan)−954$149.38$142.51K160,939
George M. Jenkins
Director
Sep 15, 2026Sale(10b5-1 plan)−560$151.33$84.74K160,116
George M. Jenkins
Director
Sep 14, 2026Sale(10b5-1 plan)−1,560$153.10$238.84K161,893
George M. Jenkins
Director
Sep 14, 2026Sale(10b5-1 plan)−6,160$152.12$937.06K163,453
George M. Jenkins
Director
Sep 14, 2026Sale(10b5-1 plan)−5,632$151.46$853.02K169,613
George M. Jenkins
Director
Sep 11, 2026Sale(10b5-1 plan)−6,520$150.62$982.04K181,096
George M. Jenkins
Director
Sep 11, 2026Sale(10b5-1 plan)−4,577$151.72$694.42K176,519
George M. Jenkins
Director
Sep 11, 2026Sale(10b5-1 plan)−1,274$153.06$195.00K175,245
Christopher P. Kiritsy
Director
Sep 2, 2026Sale−313$157.00$49.14K250
Christopher P. Kiritsy
Director
Sep 2, 2026Option exercise+313$127.20$39.81K563
Kathleen Goin
Chief Operating Officer
Aug 19, 2026Sale(10b5-1 plan)−302$156.77$47.34K0
Kathleen Goin
Chief Operating Officer
Aug 19, 2026Option exercise+2,154$7.14$15.38K2,154
Kathleen Goin
Chief Operating Officer
Aug 19, 2026Option exercise+2,148$9.08$19.50K4,302
Kathleen Goin
Chief Operating Officer
Aug 19, 2026Sale(10b5-1 plan)−1,500$151.39$227.08K2,802
Kathleen Goin
Chief Operating Officer
Aug 19, 2026Sale(10b5-1 plan)−1,998$151.80$303.30K804
Kathleen Goin
Chief Operating Officer
Aug 19, 2026Sale(10b5-1 plan)−400$153.00$61.20K404

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
20.90%
3M shares short
Days to cover
11.5
At 0M shares a day
Change since last report
+8.1%
From 2M shares
Short volume, 20 days
59.7%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Palvella Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 5,700 shares on Sep 18, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Jeffrey S. Martini
Officer
Nov 10, 202650,000$8.70MNov 10, 2026Exercise of Stock Options
Kathleen Goin
Officer
Oct 21, 20264,313$534.47KOct 21, 2026Stock Option Exercise
George M. Jenkins
Director
Oct 13, 202627,500$3.70MOct 13, 2026Private Investment
Kathleen Goin
Officer
Sep 16, 20264,302$650.55KSep 16, 2026Stock Option Exercise
George M. Jenkins
Director
Sep 11, 202627,500$4.14MSep 11, 2026Private Investment
Christopher P. Kiritsy
Director
Sep 2, 2026375$58.88KSep 2, 2026Stock Option Exercise
Kathleen Goin
Officer
Aug 19, 20264,302$647.11KAug 19, 2026Stock Option Exercise
Kathleen Goin
Officer
Jul 15, 20264,302$643.92KJul 15, 2026Stock Option Exercise
Kathleen Goin
Officer
Jun 17, 20264,302$476.37KJun 17, 2026Stock Option Exercise
Kathleen Goin
Officer
May 20, 20264,302$475.63KMay 20, 2026Stock Option Exercise
Kathleen Goin
Officer
Apr 15, 20264,302$557.24KApr 15, 2026Stock Option Exercise
Kathleen Goin
Officer
Mar 18, 20264,302$519.68KMar 18, 2026Stock Option
Kathleen Goin
Officer
Feb 19, 20264,302$344.55KFeb 18, 2026Stock Option Exercise
Kathleen Goin
Officer
Feb 18, 20264,301$344.47KFeb 18, 2026Option Exercise
Kathleen Goin
Officer
Jan 21, 20264,302$421.64KJan 21, 2026Stock Option Exercise

See a number that looks wrong?